 BOSTON, Oct. 27, 2020 GLOBE NEWSWIRE -- BridgeBio Pharma, Inc. Nasdaq: BBIO and affiliate Phoenix Tissue Repair today announced that the first patient has been dosed in a Phase 2 study of BBP-589 also known as PTR-01, an intravenously-administered recombinant collagen 7 rC7 protein replacement therapy, in patients with recessive dystrophic epidermolysis bullosa RDEB. RDEB is a rare genetic disorder caused by mutations in the gene encoding collagen type VII C7. 